2-FA
2-FA is a synthetic stimulant of the substituted amphetamine class, distinguished by a fluorine atom at the 2-position of the amphetamine structure.1 It first emerged on the online research chemical market in the 2010s as part of a series of fluorinated amphetamine analogs.12 Among these, 2-FA is regarded as the most closely resembling conventional amphetamine in its subjective effects and is frequently compared to dextroamphetamine. It is considered habit-forming.
Contents
Dosage & Duration
Dosage
Duration
Subjective Effects
The experience is that of a classical stimulant: elevated mood, increased energy and alertness, heightened sociability, and a reduced need for food and sleep. 2-FA is frequently described as a smoother, more functional alternative to amphetamine, with a comparatively clear headspace and a gentler comedown that makes it amenable to productivity-oriented use. Sensory alteration is largely absent at common doses, though visual and auditory hallucinations have been reported, typically in the context of high doses or extended sleep deprivation.
Physical
Physical effects center on stimulation and wakefulness, accompanied by appetite suppression, sweating, jaw tension, and occasional itchiness. Disturbed sleep is common in the hours following use, and repeated use can lead to weight loss.
Uncomfortable
Cognitive
The headspace is energetic and talkative, marked by euphoria, mood lift, and enhanced sociability. As the effects wear off or with repeated use, this can give way to moodiness, irritability, and aggressiveness.
Emotional
The emotional tone is predominantly positive during the experience, with negative shifts more likely during the offset or with repeated use.
Social
Visual
Visual effects are not characteristic of ordinary use; hallucinations are associated with high doses and sleep deprivation.
Auditory
Reagent Testing
Loading reagent data
Pharmacology
Pharmacodynamics
2-FA has not been formally studied to the same extent as traditional amphetamines. Based on its structural similarity to other substituted amphetamines with comparable substitution patterns, it is thought to act primarily as a dopamine and norepinephrine releasing agent. This would involve binding to and partially blocking the transporter proteins that normally clear dopamine and norepinephrine from the synaptic cleft, allowing these neurotransmitters to accumulate to elevated levels in the brain.3
Pharmacokinetics
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Tolerance
Dopaminergic stimulants, MDMA, because its full euphoric effect depends on dopamine and norepinephrine, 2-FMA
Harm Potential
Addiction & Dependence
Psychological
ModerateWith ongoing use, 2-FA may be moderately addictive and carries a substantial risk of abuse; some users can develop psychological dependence. Compulsive redosing has also been reported, and cravings may occur after sudden discontinuation.
Physical
LowWithdrawal effects may occur when dependence has developed and use is suddenly stopped, though specific physical withdrawal symptoms are not well characterized for this compound.
Toxicity
Acute cardiovascular stimulation including increased heart rate, elevated blood pressure, abnormal heartbeat, and vasoconstriction occurs during intoxication; long-term cardiovascular effects have not been studied in any scientific context.
Psychosis Risk
Abuse of amphetamine-class compounds at high dosages for prolonged periods can result in stimulant psychosis presenting with paranoia, hallucinations, or delusions.4 Reviews of amphetamine-induced psychosis indicate that approximately 5-15% of affected users may not fully recover, though antipsychotic medications are effective for acute episodes.4
Seizure Risk
Seizures are listed as a possible adverse effect, though specific incidence data for 2-FA is not available. Risk may be elevated in combination with other seizure-threshold-lowering substances.
History & Culture
2-Fluoroamphetamine emerged on the online research chemical market during the 2010s as part of a broader wave of fluorinated amphetamine derivatives. This family of compounds includes 2-FMA, 3-FA, 3-FEA, and 4-FA, which are positional isomers differing in the placement of the fluorine atom on the…
Legality
By Country
References
Source Pages
Citations
- (2005). Isomeric fluoro-methoxy-phenylalkylamines: a new series of controlled-substance analogues (designer drugs). https://doi.org/10.1016/j.forsciint.2004.05.003123
- Skov, K., Holm, N. B., Johansen, S. S., & Linnet, K.. (2012). Isomers of fluoroamphetamines detected in forensic cases in Denmark. International Journal of Legal Medicine. https://doi.org/10.1007/s00414-012-0671-01
- (n.d.). ADDERALL- dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablet. DailyMed / FDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f22635fe-821d-4cde-aa12-419f8b53db811
- (2009). Treatment for amphetamine psychosis. https://doi.org/10.1002/14651858.cd003026.pub312
- Sun, S., & Adejare, A.. (2006). Fluorinated molecules as drugs and imaging agents in the CNS. Current Topics in Medicinal Chemistry. https://doi.org/10.2174/1568026067782496951
- (n.d.). Controlled Drugs and Substances Act, Schedule I (Amphetamines). https://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-9.html1
- (n.d.). Arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants (Annexe III). https://www.legifrance.gouv.fr/loda/article_lc/LEGIARTI000039227807/2021-12-201
- (n.d.). Neue-psychoaktive-Stoffe-Gesetz (NpSG) – Anlage 1 (Stoffgruppen). https://www.gesetze-im-internet.de/npsg/BJNR261510016.html1
- (2019). § 4 NpSG. https://www.gesetze-im-internet.de/npsg/__4.html1
- (n.d.). Misuse of Drugs Act 1975, Schedule 3 Part 7 – Amphetamine Analogues. https://www.legislation.govt.nz/act/public/1975/0116/latest/DLM436723.html1
- (1971). Misuse of Drugs Act 1971. https://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I1
- (n.d.). 21 U.S.C. § 813 – Treatment of controlled substance analogues. https://www.law.cornell.edu/uscode/text/21/8131
- (n.d.). 21 CFR § 1308.12 – Schedule II controlled substances (amphetamine). https://www.law.cornell.edu/cfr/text/21/1308.121
Further Reading
Cayman Chemical - 2-Fluoroamphetamine datasheet- Cayman Chemical – 2-Fluoroamphetamine datasheet
Discrimination of Fluoroamphetamine Regioisomers by Raman Spectroscopy (2016)
Fluoroamphetamine assay validation (J Anal Toxicol 2017)
Fluoroamphetamine assay validation (J Anal Toxicol 2017)
INCB Technical Report on illicit-lab precursors (2017)- LC-MS/MS oral-fluid method including 2-FA (Anal Chim Acta 2019)
LC–MS/MS oral-fluid method including 2-FA (Anal Chim Acta 2019)- PubChem: CID 121531
Reddit: r/researchchemicals - 2-FA is actually great (2025)- Reddit: r/researchchemicals - Recreational dose discussion (2019)
- Smart - Fluorine substituent effects on bioactivity (J Fluorine Chem 2001)
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 2-FA article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.